Standout Papers

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre... 2017 2026 2020 2023 468
  1. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial (2017)
    Alice T. Shaw, Enriqueta Felip et al. The Lancet Oncology

Immediate Impact

4 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Printable molecule-selective core–shell nanoparticles for wearable and implantable sensing
2025 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
2 intermediate papers

Works of Joseph Chen being referenced

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017 Standout

Author Peers

Author Last Decade Papers Cites
Joseph Chen 507 433 234 27 762
M. Puglisi 399 531 256 36 973
Engracio P. Cortes 368 438 118 22 893
J. Fra 521 638 284 39 890
J. Wendall Goodwin 326 513 185 34 984
Shuncong Wang 203 337 203 38 738
Dengfeng Ren 332 500 175 43 773
Davide Lombardi 301 593 200 57 968
Maja J. De Jonge 296 444 467 43 835
Ting Liu 317 332 350 24 753
A. Bowman 174 346 168 34 719

All Works

Loading papers...

Rankless by CCL
2026